| First Author | Januel C | Year | 2022 |
| Journal | Cell Mol Life Sci | Volume | 79 |
| Issue | 8 | Pages | 441 |
| PubMed ID | 35864358 | Mgi Jnum | J:355194 |
| Mgi Id | MGI:7737842 | Doi | 10.1007/s00018-022-04450-8 |
| Citation | Januel C, et al. (2022) Moxifloxacin rescues SMA phenotypes in patient-derived cells and animal model. Cell Mol Life Sci 79(8):441 |
| abstractText | Spinal muscular atrophy (SMA) is a genetic disease resulting in the loss of alpha-motoneurons followed by muscle atrophy. It is caused by knock-out mutations in the survival of motor neuron 1 (SMN1) gene, which has an unaffected, but due to preferential exon 7 skipping, only partially functional human-specific SMN2 copy. We previously described a Drosophila-based screening of FDA-approved drugs that led us to discover moxifloxacin. We showed its positive effect on the SMN2 exon 7 splicing in SMA patient-derived skin cells and its ability to increase the SMN protein level. Here, we focus on moxifloxacin's therapeutic potential in additional SMA cellular and animal models. We demonstrate that moxifloxacin rescues the SMA-related molecular and phenotypical defects in muscle cells and motoneurons by improving the SMN2 splicing. The consequent increase of SMN levels was higher than in case of risdiplam, a potent exon 7 splicing modifier, and exceeded the threshold necessary for a survival improvement. We also demonstrate that daily subcutaneous injections of moxifloxacin in a severe SMA murine model reduces its characteristic neuroinflammation and increases the SMN levels in various tissues, leading to improved motor skills and extended lifespan. We show that moxifloxacin, originally used as an antibiotic, can be potentially repositioned for the SMA treatment. |
